Terms: = Bone cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
1187 results:
1. Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy.
Yan J; Bhadane R; Ran M; Ma X; Li Y; Zheng D; Salo-Ahen OMH; Zhang H
Nat Commun; 2024 May; 15(1):3684. PubMed ID: 38693181
[TBL] [Abstract] [Full Text] [Related]
2. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
3. Outcomes of the patients with metastatic male breast cancer.
Dogan I; Khanmammadov N; Ozkurt S; Aydiner A; Saip P
J Cancer Res Ther; 2024 Jan; 20(1):98-102. PubMed ID: 38554305
[TBL] [Abstract] [Full Text] [Related]
4. A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, her2-Negative bone Metastatic Breast cancer.
Magno E; Bussard KM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542380
[TBL] [Abstract] [Full Text] [Related]
5. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV her2-positive Breast cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002
[TBL] [Abstract] [Full Text] [Related]
6. Surgical Resection of Primary Tumor for bone Metastatic Breast cancer Patients at Initial Presentation.
Kitsuya N; Matsuoka M; Onodera T; Yokota I; Iwasaki K; Suzuki Y; Hamasaki M; Kondo E; Iwasaki N
Anticancer Res; 2024 Apr; 44(4):1591-1601. PubMed ID: 38537990
[TBL] [Abstract] [Full Text] [Related]
7. Discussing the safety and effectiveness of transcatheter arterial embolization combined with intravenous chemotherapy in treating locally advanced breast cancer.
Zhang J; Zhang J; Niu X; Zhou Y; Guo Y; Wang Y; Shou F
Sci Rep; 2024 Mar; 14(1):6003. PubMed ID: 38472493
[TBL] [Abstract] [Full Text] [Related]
8. Detection of her2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract] [Full Text] [Related]
9. BRD4-targeting PROTACs Synergize With Chemotherapeutics Against Osteosarcoma Cell Lines.
Lang C; Stickler S; Rath B; Teufelsbauer M; Weigl L; Hohenegger M; Hamilton G
Anticancer Res; 2024 Mar; 44(3):971-980. PubMed ID: 38423674
[TBL] [Abstract] [Full Text] [Related]
10. Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with her2-enriched breast cancer.
Li Y; Qin J; Chen G; Wu W; Sun X
Int J Clin Oncol; 2024 Apr; 29(4):427-441. PubMed ID: 38411882
[TBL] [Abstract] [Full Text] [Related]
11. An Integrated Care Approach to Improve Well-Being in Breast cancer Patients.
Fabi A; Rossi A; Mocini E; Cardinali L; Bonavolontà V; Cenci C; Magno S; Barberi V; Moretti A; Besharat ZM; Iolascon G; Baldari C; Ferretti E; Botticelli A; Paris I; Scambia G; Migliaccio S
Curr Oncol Rep; 2024 Apr; 26(4):346-358. PubMed ID: 38400984
[TBL] [Abstract] [Full Text] [Related]
12. Capecitabine is effective as palliative chemotherapy in a patient with androgen receptor and her2 positive metastatic salivary duct carcinoma. A case report.
Čavka L; Zakotnik B
J Cancer Res Ther; 2023 Oct; 19(7):2048-2051. PubMed ID: 38376316
[TBL] [Abstract] [Full Text] [Related]
13. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract] [Full Text] [Related]
14. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and her2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
Palmieri C; Linden H; Birrell SN; Wheelwright S; Lim E; Schwartzberg LS; Dwyer AR; Hickey TE; Rugo HS; Cobb P; O'Shaughnessy JA; Johnston S; Brufsky A; Tilley WD; Overmoyer B
Lancet Oncol; 2024 Mar; 25(3):317-325. PubMed ID: 38342115
[TBL] [Abstract] [Full Text] [Related]
15. [A Case of Breast cancer Complicated by Fibrous Dysplasia That Was Difficult to Differentiate from bone Metastasis].
Makino Y; Otani A; Hikino H; Murata Y; Miura H; Harada A
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1465-1467. PubMed ID: 38303309
[TBL] [Abstract] [Full Text] [Related]
16. [A Case of Complete Remission in a Patient with Synchronous Double cancers of the Breast and Lung].
Hayakawa T; Hasegawa K; Maejima K; Takatsuno Y; Kaneko J; Higashi Y; Isogai J; Tagawa K; Yoshida H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1459-1461. PubMed ID: 38303307
[TBL] [Abstract] [Full Text] [Related]
17. [A Case of Postoperative Recurrence of Bilateral Breast cancer in Which Stable Disease Condition Was Achieved by Olaparib].
Terakawa H; Kawata C; Kurokawa Y; Ooe Y; Mohri R; Hirata M; Moriyama H; Kinoshita J; Kawashima H; Inaki N
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1414-1416. PubMed ID: 38303292
[TBL] [Abstract] [Full Text] [Related]
18. [Elderly Advanced Breast cancer Effectively Treated with Locoregional Therapy-A Case Report].
Adachi K; Nagae J; Kubota H; Suzuki S; Hirano T; Sakurai K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1834-1836. PubMed ID: 38303223
[TBL] [Abstract] [Full Text] [Related]
19. [A Case of Recurrent Gastric cancer with Long-Term Control via Two Resections and Multidisciplinary Treatment Including Nivolumab].
Bungo M; Takeno A; Hirao M; Hamakawa T; Yamamoto M; Matsui Y; Tokuyama S; Toshiyama R; Kawai K; Takahashi Y; Sakai K; Doi T; Goto K; Kato T; Takami K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1715-1717. PubMed ID: 38303183
[TBL] [Abstract] [Full Text] [Related]
20. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
[Next]
